We hypothesized that Galantamine, an acetyl choline esterase inhibitor and an FDA approved treatment of Alzheimer’s disease, will reduce hyperoxic brain injury in neonatal mice and will improve learning and memory. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.